Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento

Asherson, 2003, Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines, Lupus., 12, 530, 10.1191/0961203303lu394oa Hughes, 1993, The antiphospholipid syndrome: Ten years on, Lancet., 342, 341, 10.1016/0140-6736(93)91477-4 Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost., 4, 295, 10.1111/j.1538-7836.2006.01753.x Bucciarelli, 2006, Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients, Arthritis Rheum., 54, 2568, 10.1002/art.22018 De Jesus, 2014, 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome, Autoimmun Rev., 13, 795, 10.1016/j.autrev.2014.02.003 Arnaud, 2017, Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's, Autoimmun Rev., 16, 1103, 10.1016/j.autrev.2017.09.003 Giannakopoulos, 2013, The pathogenesis of the antiphospholipid syndrome, N Engl J Med., 368, 1033, 10.1056/NEJMra1112830 Cervera, 2005, Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome, Ann Rheum Dis., 64, 1205, 10.1136/ard.2004.025759 Grupo de trabajo para la actualización del Manual de Elaboración de GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Actualización del Manual Metodológic. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; Zaragoza: Instituto Aragonés de Ciencias de la Salud (IACS); 2016. Disponible en: http://portal.guiasalud.es/emanuales/elaboracion_2/?capitulo Sater, 2012, Anti-phosphatidylserine, anti-cardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in recurrent miscarriage at 8-12 gestational weeks, Eur J Obstet Gynecol Reprod Biol., 163, 170, 10.1016/j.ejogrb.2012.04.001 Silver, 2013, Antiphospholipid antibodies in stillbirth, Obstet Gynecol., 122, 641, 10.1097/AOG.0b013e3182a1060e Abou-Nassar, 2011, The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis, Thromb Res., 128, 77, 10.1016/j.thromres.2011.02.006 Helgadottir, 2012, The association of antiphospholipid antibodies with intrauterine fetal death: A case-control study, Thromb Res., 130, 32, 10.1016/j.thromres.2011.11.029 Alijotas-Reig, 2010, Anti-beta(2)-glycoprotein-I and anti-phosphatidylserine antibodies in women with spontaneous pregnancy loss, Fertil Steril., 93, 2330, 10.1016/j.fertnstert.2009.01.089 Oron, 2011, Contribution of the addition of anti-beta2-glycoprotein to the classification of antiphospholipid syndrome in predicting adverse pregnancy outcome, J Matern Fetal Neonatal Med., 24, 606, 10.3109/14767058.2010.511339 Pengo, 2010, Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, J Thromb Haemost., 8, 237, 10.1111/j.1538-7836.2009.03674.x Saccone, 2017, Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: The PREGNANTS study, Am J Obstet Gynecol., 216 Bergrem, 2010, The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis — a population-based case-control study, Thromb Res., 125, e222, 10.1016/j.thromres.2009.12.006 Liu, 2013, Anti-beta2 glycoprotein I antibodies and pregnancy outcome in antiphospholipid syndrome, Acta Obstet Gynecol Scand., 92, 234, 10.1111/aogs.12038 Cojocaru, 2007, Evaluation of antiphospholipid antibodies in young women with ischemic stroke, Rom J Intern Med., 45, 201 De Groot, 2005, Lupus anticoagulants and the risk of a first episode of deep venous thrombosis, J Thromb Haemost., 3, 1993, 10.1111/j.1538-7836.2005.01485.x Deeb, 2009, Prevalence of antiphospholipid antibodies in Syrian patients with thrombosis, Iran J Immunol., 6, 154 Hernandez-Molina, 2013, The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome, Clin Exp Rheumatol., 31, 382 Pengo, 2005, Antibody profiles for the diagnosis of antiphospholipid syndrome, Thromb Haemost., 93, 1147, 10.1160/TH04-12-0839 Ruffatti, 2011, Risk factors for a first thrombotic event in antiphospholipid antibody carriers: A prospective multicentre follow-up study, Ann Rheum Dis., 70, 1083, 10.1136/ard.2010.142042 Ruffatti, 2009, Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study, Ann Rheum Dis., 68, 397, 10.1136/ard.2008.096669 Urbanus, 2009, Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: A case-control study, Lancet Neurol., 8, 998, 10.1016/S1474-4422(09)70239-X Zoghlami-Rintelen, 2005, The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant, J Thromb Haemost., 3, 1160, 10.1111/j.1538-7836.2005.01394.x Bashshur, 2003, Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: A prospective study, Retina., 23, 486, 10.1097/00006982-200308000-00007 Christopher, 1999, Anticardiolipin antibodies: A study in cerebral venous thrombosis, Acta Neurol Scand., 99, 121, 10.1111/j.1600-0404.1999.tb00669.x Finazzi, 1996, Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry, Am J Med., 100, 530, 10.1016/S0002-9343(96)00060-5 Ginsburg, 1992, Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis, Ann Intern Med., 117, 997, 10.7326/0003-4819-117-12-997 Palomo, 2004, Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis, Clin Rheumatol., 23, 129, 10.1007/s10067-003-0846-7 Tektonidou, 2009, Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies, Arthritis Rheum., 61, 29, 10.1002/art.24232 Turiel, 2005, Thrombotic risk factors in primary antiphospholipid syndrome: A 5-year prospective study, Stroke., 36, 1490, 10.1161/01.STR.0000170645.40562.09 Amory, 2015, Antiphospholipid antibodies and recurrent thrombotic events: Persistence and portfolio, Cerebrovasc Dis., 40, 293, 10.1159/000441362 Forastiero, 2005, A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis, J Thromb Haemost., 3, 1231, 10.1111/j.1538-7836.2005.01295.x Tektonidou, 2000, Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome, Qjm., 93, 523, 10.1093/qjmed/93.8.523 Zanon, 1999, Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: Prevalence and association with recurrent thromboembolism, Thromb Res., 96, 269, 10.1016/S0049-3848(99)00105-X Bertolaccini, 2014, 14th International Congress on Antiphospholipid Antibodies Task Force Report on antiphospholipid syndrome laboratory diagnostics and trends, Autoimmun Rev., 13, 917, 10.1016/j.autrev.2014.05.001 Pengo, 2015, Antiphospholipid syndrome: Antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk, J Thromb Haemost., 13, 782, 10.1111/jth.12865 Pengo, 2015, Antibodies to Domain 4/5 (Dm4/5) of beta2-glycoprotein 1 (beta2GP1) in different antiphospholipid (aPL) antibody profiles, Thromb Res., 136, 161, 10.1016/j.thromres.2015.04.031 Meijide, 2013, The clinical relevance of IgA anticardiolipin and IgA anti-beta2 glycoprotein I antiphospholipid antibodies: A systematic review, Autoimmun Rev., 12, 421, 10.1016/j.autrev.2012.08.002 Bertolaccini, 2013, Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant, Thromb Haemost., 109, 207, 10.1160/TH12-07-0527 Sciascia, 2014, New tests to detect antiphospholipid antibodies: Antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies, Curr Rheumatol Rep., 16, 415, 10.1007/s11926-014-0415-x Amengual, 2017, Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: Results of an international multicentre study, Lupus., 26, 266, 10.1177/0961203316660203 Sanmarco, 2001, Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses, Thromb Haemost., 85, 800, 10.1055/s-0037-1615751 Sanmarco, 2007, Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies, Thromb Haemost., 97, 949, 10.1160/TH06-10-0604 Staub, 2012, Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome, Autoimmun Rev., 12, 230, 10.1016/j.autrev.2012.07.008 Staub, 1989, Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis, Ann Rheum Dis., 48, 166, 10.1136/ard.48.2.166 Blaschek, 1988, Relation of antivimentin antibodies to anticardiolipin antibodies in systemic lupus erythematosus, Ann Rheum Dis., 47, 708, 10.1136/ard.47.9.708 Ortona, 2010, Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome, Blood., 116, 2960, 10.1182/blood-2010-04-279208 Arnold, 2001, Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage, Br J Haematol., 113, 911, 10.1046/j.1365-2141.2001.02812.x De Laat, 2006, Annexin A5 polymorphism (-1CT) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome, Ann Rheum Dis., 65, 1468, 10.1136/ard.2005.045237 Nojima, 2001, Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications, Clin Chem., 47, 1008, 10.1093/clinchem/47.6.1008 Cesarman-Maus, 2006, Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome, Blood., 107, 4375, 10.1182/blood-2005-07-2636 Hajjar, 1994, An endothelial cell receptor for plasminogen/tissue plasminogen activator I. Identity with annexin II, J Biol Chem., 269, 21191, 10.1016/S0021-9258(17)31947-6 Kaczan-Bourgois, 1996, Increased content of annexin II (p36) and p11 in human placenta brush-border membrane vesicles during syncytiotrophoblast maturation and differentiation, Placenta., 17, 669, 10.1016/S0143-4004(96)80017-8 Borrell, 2008, IgM anti-protein S antibodies as a risk factor for venous thrombosis, Haematologica., 93, 1115, 10.3324/haematol.12575 Sciascia, 2016, Thrombotic risk assessment in antiphospholipid syndrome: The role of new antibody specificities and thrombin generation assay, Clin Mol Allergy., 14, 6, 10.1186/s12948-016-0043-2 Pengo, 2009, Update of the guidelines for lupus anticoagulant detection Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, J Thromb Haemost., 7, 1737, 10.1111/j.1538-7836.2009.03555.x Moore, 2014, Recent guidelines and recommendations for laboratory detection of lupus anticoagulants, Semin Thromb Hemost., 40, 163, 10.1055/s-0033-1364185 Parmar K, Lefkou E, Doughty H, Connor P, Hunt BJ. The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist. Blood Coagulation & Fibrinolysis: June 2009 - Volume 20 - Issue 4 - p 271-275. Moore, 2007, Combining Taipan snake venom time/Ecarin time screening with the mixing studies of conventional assays increases detection rates of lupus anticoagulants in orally anticoagulated patients, Thromb J., 5, 12, 10.1186/1477-9560-5-12 Tripodi, 2016, Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: Communication from the SSC of the ISTH, J Thromb Haemost., 14, 7, 10.1111/jth.13481 Sciascia, 2016, Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome, Rheumatology (Oxford), 55, 1726, 10.1093/rheumatology/kev445 Crowl, 2014, Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant, Ann Pharmacother., 48, 1479, 10.1177/1060028014546361 Lawrie, 1997, Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome, Br J Haematol., 98, 887, 10.1046/j.1365-2141.1997.3283145.x Efthymiou, 2015, Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome, Thromb Res., 135, 7, 10.1016/j.thromres.2015.03.030 Levine, 2004, Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke, JAMA., 291, 576, 10.1001/jama.291.5.576 Kearon, 2012, Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest., 141, e419S, 10.1378/chest.11-2301 Kearon, 2016, Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report, Chest., 149, 315, 10.1016/j.chest.2015.11.026 Cuadrado, 2014, Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: A prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS), Rheumatology (Oxford)., 53, 275, 10.1093/rheumatology/ket313 Ruiz-Irastorza, 2011, Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on Antiphospholipid Antibodies, Lupus., 20, 206, 10.1177/0961203310395803 Hisada, 2017, Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: A longitudinal study, J Thromb Haemost., 15, 7, 10.1111/jth.13763 Oku, 2017, How to identify high-risk APS patients: Clinical utility and predictive values of validated scores, Curr Rheumatol Rep., 19, 51, 10.1007/s11926-017-0674-4 Pengo, 2011, Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study, Blood., 118, 8, 10.1182/blood-2011-03-340232 Giron-Gonzalez, 2004, Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: Prospective analysis of 404 individuals, J Rheumatol., 31, 7 Erkan, 2007, Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals, Arthritis Rheum., 56, 2382, 10.1002/art.22663 Arnaud, 2015, Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies, Autoimmun Rev., 14, 192, 10.1016/j.autrev.2014.10.019 Mustonen, 2014, Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study, Lupus., 23, 1468, 10.1177/0961203314545410 Comellas-Kirkerup, 2010, Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: A 6-year follow-up study, Blood., 116, 3058, 10.1182/blood-2010-05-283507 Demetrio Pablo, 2017, Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria, Med Clin (Barc)., 148, 394, 10.1016/j.medcli.2016.11.026 Hereng, 2008, Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients, Lupus., 17, 11, 10.1177/0961203307084724 Bouvier, 2014, Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: The NOH-APS observational study, Blood., 123, 404, 10.1182/blood-2013-08-522623 Mak, 2010, Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: A meta-analysis of randomized controlled trials and meta-regression, Rheumatology (Oxford)., 49, 281, 10.1093/rheumatology/kep373 Ziakas, 2010, Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: A systematic review and meta-analysis, Obstet Gynecol., 115, 1256, 10.1097/AOG.0b013e3181deba40 Van Hoorn, 2016, Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: The FRUIT-RCT, Eur J Obstet Gynecol Reprod Biol., 197, 168, 10.1016/j.ejogrb.2015.12.011 Amengual, 2015, Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: A systematic review, Lupus., 24, 1135, 10.1177/0961203315578765 Del Ross, 2013, Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: A retrospective study, J Rheumatol., 40, 425, 10.3899/jrheum.120576 Kahwa, 2006, Anticardiolipin antibodies in Jamaican primiparae, J Obstet Gynaecol., 26, 122, 10.1080/01443610500443352 Cowchock, 1997, Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial, Am J Obstet Gynecol., 176, 1099, 10.1016/S0002-9378(97)70409-5 Lazzaroni, 2017, OP0046 Risk factors for adverse pregnancy outcome in antiphospholipid antibodies carriers: Results from a multicenter Italian cohort over 20 years of experience, Ann Rheum Dis., 76, 70 Buller, 2004, Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest., 126 Derksen, 2010, Towards evidence-based treatment of thrombotic antiphospholipid syndrome, Lupus., 19, 470, 10.1177/0961203309361483 Erkan, 2014, 14th International Congress on Antiphospholipid Antibodies: Task force report on antiphospholipid syndrome treatment trends, Autoimmun Rev., 13, 685, 10.1016/j.autrev.2014.01.053 Espinosa, 2009, Thromboprophylaxis and obstetric management of the antiphospholipid syndrome, Expert Opin Pharmacother., 10, 601, 10.1517/14656560902772302 Farmer-Boatwright, 2009, Venous thrombosis in the antiphospholipid syndrome, Arterioscler Thromb Vasc Biol., 29, 321, 10.1161/ATVBAHA.108.182204 Lim, 2016, Prevention of thrombosis in antiphospholipid syndrome, Hematology Am Soc Hematol Educ Program., 2016, 707, 10.1182/asheducation-2016.1.707 Lim, 2006, Management of antiphospholipid antibody syndrome: A systematic review, JAMA., 295, 1050, 10.1001/jama.295.9.1050 Meroni, 2003, Venous thromboembolism in the antiphospholipid syndrome: Management guidelines for secondary prophylaxis, Lupus., 12, 504, 10.1191/0961203303lu389oa Khamashta, 1995, The management of thrombosis in the antiphospholipid-antibody syndrome, N Engl J Med., 332, 993, 10.1056/NEJM199504133321504 Crowther, 2003, A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome, N Engl J Med., 349, 1133, 10.1056/NEJMoa035241 Finazzi, 2005, A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS), J Thromb Haemost., 3, 848, 10.1111/j.1538-7836.2005.01340.x Ost, 2005, Duration of anticoagulation following venous thromboembolism: A meta-analysis, JAMA., 294, 706, 10.1001/jama.294.6.706 Ruiz-Irastorza, 2007, A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies, Arthritis Rheum., 57, 1487, 10.1002/art.23109 Ames, 2005, Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: An 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia, Thromb Haemost., 93, 694, 10.1160/TH04-11-0723 Derksen, 1993, Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment, Ann Rheum Dis., 52, 689, 10.1136/ard.52.9.689 Krnic-Barrie, 1997, A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis, Arch Intern Med., 157, 2101, 10.1001/archinte.1997.00440390101013 Munoz-Rodriguez, 1999, Clinical study and follow-up of 100 patients with the antiphospholipid syndrome, Semin Arthritis Rheum., 29, 182, 10.1016/S0049-0172(99)80029-8 Rosove, 1992, Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients, Ann Intern Med., 117, 303, 10.7326/0003-4819-117-4-303 Ruiz-Irastorza, 2002, Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: Analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5, Arch Intern Med., 162, 1164, 10.1001/archinte.162.10.1164 Ginsberg, 1995, Antiphospholipid antibodies and venous thromboembolism, Blood., 86, 3685, 10.1182/blood.V86.10.3685.bloodjournal86103685 Prandoni, 1996, Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation, Thromb Haemost., 75, 859, 10.1055/s-0038-1650380 Rance, 1997, Anticardiolipin antibodies and recurrent thromboembolism, Thromb Haemost., 77, 221, 10.1055/s-0038-1655939 Schulman, 1998, Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy, Am J Med., 104, 332, 10.1016/S0002-9343(98)00060-6 Oliva Berini, 2008, Comparison of quality and hemorragic risk of oral anticoagulant therapy using acenocoumarol versus warfarin, Med Clin (Barc)., 131, 96, 10.1157/13124012 Pattacini, 1994, A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol), Thromb Haemost., 71, 188 Kearon, 1999, A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism, N Engl J Med., 340, 901, 10.1056/NEJM199903253401201 Kearon, 2008, Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition), Chest., 133, 454s, 10.1378/chest.08-0658 Garcia, 2013, Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: A systematic review, Blood., 122, 817, 10.1182/blood-2013-04-496257 Riancho-Zarrabeitia, 2017, Serological evolution in women with positive antiphospholipid antibodies, Semin Arthritis Rheum., 47, 397, 10.1016/j.semarthrit.2017.05.001 Sciascia, 2017, Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?, Autoimmun Rev., 16, 1109, 10.1016/j.autrev.2017.09.004 Okuma, 2009, Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome, Int J Med Sci., 7, 15 Kernan, 2014, Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association, Stroke., 45, 2160, 10.1161/STR.0000000000000024 Legault, 2016, Prevention of recurrent thrombosis in antiphospholipid syndrome: Different from the general population?, Curr Rheumatol Rep., 18, 26, 10.1007/s11926-016-0573-0 Chighizola, 2018, Management of thrombotic antiphospholipid syndrome, Semin Thromb Hemost., 44, 419, 10.1055/s-0036-1597282 Keeling, 2012, Guidelines on the investigation and management of antiphospholipid syndrome, Br J Haematol., 157, 47, 10.1111/j.1365-2141.2012.09037.x Ruiz-Irastorza, 2010, Antiphospholipid syndrome, Lancet., 376, 1498, 10.1016/S0140-6736(10)60709-X Chighizola, 2015, Treatment of thrombotic antiphospholipid syndrome: The rationale of current management — an insight into future approaches, J Immunol Res., 2015, 951424, 10.1155/2015/951424 Bick, 1999, Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: Efficacy and safety — a preliminary report, Clin Appl Thromb Hemost., 5, S67, 10.1177/10760296990050S112 Vargas-Hitos, 2011, Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome, Ann Rheum Dis., 70, 1652, 10.1136/ard.2011.150268 Scoble, 2011, Management of refractory anti-phospholipid syndrome, Autoimmun Rev., 10, 669, 10.1016/j.autrev.2011.04.030 Rosa, 2015, Difficult clinical situations in the antiphospholipid syndrome, Curr Rheumatol Rep., 17, 29, 10.1007/s11926-015-0502-7 Fujieda, 2012, Dual antiplatelet therapy as prophylaxis of recurrent arterial thrombosis in patients with antiphospholipid syndrome, Arthritis Rheum, 64, S1036 Belizna, 2015, Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome, Autoimmun Rev., 14, 358, 10.1016/j.autrev.2014.12.006 Nuri, 2017, Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome, Immunol Res., 65, 17, 10.1007/s12026-016-8812-z Broder, 2013, Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus, J Rheumatol., 40, 30, 10.3899/jrheum.120157 Schmidt-Tanguy, 2013, Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients, J Thromb Haemost., 11, 1927, 10.1111/jth.12363 Owens, 2014, The antithrombotic effects of statins, Annu Rev Med., 65, 433, 10.1146/annurev-med-051812-145304 Erkan, 2014, A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients, Ann Rheum Dis., 73, 1176, 10.1136/annrheumdis-2013-203622 Erkan, 2013, A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome, Arthritis Rheum., 65, 464, 10.1002/art.37759 Pons, 2015, [Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: Analysis of 24 cases from the bibliography review], Med Clin (Barc)., 144, 97, 10.1016/j.medcli.2014.01.034 Sciascia, 2012, Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin, Clin Exp Rheumatol., 30, 409 Tenti, 2013, Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy, Clin Exp Rheumatol., 31, 877 Chaturvedi, 2015, The antiphospholipid syndrome: Still an enigma, Hematology Am Soc Hematol Educ Program., 2015, 53, 10.1182/asheducation-2015.1.53 Khamashta, 2016, Antiphospholipid syndrome, Best Pract Res Clin Rheumatol., 30, 133, 10.1016/j.berh.2016.04.002 Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med., 363, 2499, 10.1056/NEJMoa1007903 Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med., 369, 799, 10.1056/NEJMoa1302507 Buller, 2013, Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med., 369, 1406, 10.1056/NEJMoa1306638 Goldhaber, 2016, Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER(R) RE-COVER II, and RE-MEDY, Vasc Med., 21, 506, 10.1177/1358863X16668588 Cohen, 2016, Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2/3, non-inferiority trial, Lancet Haematol., 3, e426, 10.1016/S2352-3026(16)30079-5 Woller, 2016, Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: Study rationale and design (ASTRO-APS), Clin Appl Thromb Hemost., 22, 239, 10.1177/1076029615615960 Chighizola, 2014, New oral anticoagulants in thrombotic antiphospholipid syndrome, Lupus., 23, 1279, 10.1177/0961203314540968 White, 2016, Role of novel oral anticoagulants in the treatment of antiphospholipid syndrome, Hosp Pharm., 51, 759, 10.1310/hpj5109-759 Pengo, 2018, Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome, Blood., 32, 1365, 10.1182/blood-2018-04-848333 https:// www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2019/NI_MUH_FV-8-2019-anticoagulantes-orales.htm